



STAFF REPORT

# Artificial Blood:

*Global Markets to 2027*

April 2018



*BCC Research Staff*

Report Code: BIO164A

# Table of Contents

- Chapter 1: Introduction ..... 1**
  - Study Goals and Objectives..... 1
  - Reasons for Doing This Study..... 1
  - Contribution of the Study and Intended Audience..... 1
  - Scope of Report..... 2
  - Information Sources..... 2
  - Methodology..... 2
  - Geographic Breakdown..... 3
  - Analysts’ Credentials..... 7
  - Related BCC Research Reports..... 7
  
- Chapter 2: Summary and Highlights..... 9**
  - Introduction ..... 9
  
- Chapter 3: Market Overview..... 12**
  - Introduction ..... 12
  - Is There a Problem with Human Blood? ..... 13
  - Emerging Needs for Artificial Blood..... 14
    - Artificial Blood Will Be Useful in Dealing with the Risks of Infection..... 14
    - Artificial Blood Will Help to Decrease the Load on Donor Blood Supply ..... 14
    - Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System ..... 14
    - Artificial Blood Has the Potential to Lower Costs of the Blood System ..... 15
  - Hurdles in the Development of Artificial Blood Products..... 15
  - Ideal Characteristics of Artificial Blood ..... 18
  - Artificial Blood Over Human Blood ..... 18
  - Challenges in Artificial Blood Development..... 20
  
- Chapter 4: Market Estimation ..... 22**
  - Market Dynamics: Factors and Impact Analysis ..... 22
    - Time factor ..... 22
    - Product Preference ..... 22
    - Regulatory Approvals ..... 22
    - Product Demand ..... 23
    - Product Acceptance ..... 23
    - Cost and Effectiveness..... 23
    - Intense Competition in the Market..... 24
    - Clinical Trials..... 24
    - Technologies..... 24
    - Product Pricing ..... 25
    - Patient Group ..... 25
  - Global Potential Market..... 25
    - Surgeries and Death Cases ..... 25
  - Market Penetration ..... 28
  
- Chapter 5: Market by Source ..... 32**
  - Introduction ..... 32
  - Artificial Blood Developed from Human Blood..... 33
  - Artificial Blood Developed from Animal Blood ..... 34
  - Artificial Blood Developed Using Recombinant Technology ..... 34

Surface Modified Hemoglobin .....	37
Cross-Linked Hemoglobin.....	37
Polymerized Hemoglobin .....	37
<b>Chapter 6: Market by Type .....</b>	<b>41</b>
Introduction .....	41
Perfluorocarbon Emulsions.....	43
General Characteristics of Perfluorocarbons .....	44
Emulsion Selection .....	45
Historical Developments of Perfluorocarbon Emulsions .....	46
First Generation of PFCs.....	47
Second Generation of PFCs .....	48
Third Generation of PFCs .....	49
Hemoglobin Based Oxygen Carriers .....	51
General Characteristics of HBOCs .....	52
Historical Events: - Hemoglobin Solutions .....	53
<b>Chapter 7: Market Breakdown by Application .....</b>	<b>58</b>
Introduction .....	58
Surgeries.....	58
Emergency Resuscitation .....	58
For Short-term Use.....	58
Where More Effective Than Human Blood .....	59
Rejections Due to Religious Beliefs .....	59
Global Potential Artificial Blood Market, by Application .....	59
<b>Chapter 8: Market Breakdown by Region .....</b>	<b>62</b>
Introduction .....	62
North America.....	63
United States .....	63
Canada.....	68
Mexico .....	74
Europe.....	80
Germany.....	80
France .....	86
United Kingdom.....	91
Italy.....	97
Spain .....	103
Russia.....	108
Asia Pacific .....	114
China.....	114
India.....	119
Japan.....	126
Australia .....	132
Rest of The World .....	138
Brazil .....	138
South Africa.....	144
<b>Chapter 9: Regulation and Patent Review.....</b>	<b>151</b>
Introduction .....	151
FDA Regulation.....	151
FDA Good Manufacturing Practices and Reporting.....	151

Patent Review .....	152
<b>Chapter 10: Competitive Landscape .....</b>	<b>155</b>
Introduction .....	155
<b>Chapter 11: Product Analysis .....</b>	<b>159</b>
Introduction .....	159
Product Safety .....	160
Product Effectiveness .....	160
Product Cost .....	160
Legal Implications .....	161
Hemolink .....	161
Product offered by Hemosol BioPharma Inc. ....	161
Clinical Trials .....	163
HemAssist .....	167
Product offered by Baxter Healthcare Corp. ....	167
Hemopure .....	171
Product offered by Biopure Corp./OPK Biotech .....	171
Clinical Trials .....	174
HemoSpan .....	193
Product offered by Sangart, Inc. ....	193
Clinical Trials .....	196
HemoTech .....	202
Product offered by HemoBioTech, Inc. ....	202
Clinical Trials .....	204
DDFPe .....	210
Product offered by NuvOx Pharma LLC .....	210
Clinical Trials .....	213
Oxycyte .....	220
Product offered by Tenax Therapeutics, Inc. ....	220
Clinical Trials .....	222
Oxygent .....	232
Product offered by Alliance Pharmaceutical Corp. ....	232
Clinical Trials .....	234
Vidaphor .....	237
Product offered by FluorO2 Therapeutics, Inc. ....	237
Clinical Trials .....	239
PHER-O2 .....	239
Product offered by Sanguine Biosciences .....	239
Clinical Trials .....	242
Polyheme .....	243
Product Offered by Northfield Laboratories Inc. ....	243
Clinical Trials .....	245
Sanguinate .....	249
Product Offered by Prolong Pharmaceuticals, LLC .....	249
Clinical Trials .....	251
<b>Chapter 12: Company Profiles .....</b>	<b>259</b>
<b>Appendix .....</b>	<b>279</b>
<b>About BCC Research .....</b>	<b>281</b>

About BCC Research..... 282  
BCC Membership ..... 282  
BCC Custom Research ..... 282

# List of Tables

Summary Table Global Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	9
Table 1 Historical Events Related to Blood Transfusion .....	16
Table 2 Potential Benefits and Application Areas of Artificial Blood .....	18
Table 3 The Challenges Associated with the Development of Artificial Blood .....	20
Table 4 Average Number of Blood Units Required During Particular Medical Condition .....	26
Table 5 Market Penetration Cases Based on Set of Assumptions .....	28
Table 6 Global Potential Artificial Blood Market, Through 2027 (\$ Millions).....	30
Table 7 Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions .....	33
Table 8 Pros and Cons of Artificial Blood Developed from Human Blood .....	33
Table 9 Pros and Cons of Artificial Blood Developed from Animal Blood .....	34
Table 10 Pros & Cons of Artificial Blood Developed from Recombinant Blood.....	36
Table 11 Summary of Acellular Hb-Based Oxygen Carriers .....	38
Table 12 Hemoglobin Based Oxygen Carrier Products and Approval Status.....	39
Table 13 Potential Clinical Applications of Oxygen Carriers .....	43
Table 14 Composition of PFC Emulsion Based Artificial Blood Products .....	44
Table 15 First-Generation Perfluorocarbon Emulsions Used in Medicine and Biology.....	48
Table 16 Comparative Study of Second-Generation PFCs .....	49
Table 17 PFC Emulsion Products and Current Status.....	50
Table 18 Comparative Study Between RBCs and HBOCs .....	54
Table 19 HBOC Solutions Transfusion: Side Effects and Possible Causes .....	55
Table 20 HBOC Products Developed by Various Companies .....	56
Table 21 Global Potential Artificial Blood Market, by Application, Through 2027 (\$ Millions).....	60
Table 22 United States: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	68
Table 23 Canada: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	73
Table 24 Mexico: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	80
Table 25 Germany: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	85
Table 26 France: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	90
Table 27 U.K.: Potential Artificial Blood Market, Through 2027 (\$ Millions).....	96
Table 28 Italy: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	102
Table 29 Spain: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	107
Table 30 Russia: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	113
Table 31 China: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	118
Table 32 India: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	125
Table 33 Japan: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	131
Table 34 Australia: Potential Artificial Blood Market, Through 2027 (\$ Millions).....	137
Table 35 Brazil: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	143
Table 36 South Africa: Potential Artificial Blood Market, Through 2027 (\$ Millions) .....	149
Table 37 Summary of Three Clinical Trial Phases Recognized by FDA.....	152
Table 38 Hemolink: Raw Material and Method Overview.....	161
Table 39 Hemolink: Advantages and Disadvantages .....	162
Table 40 Hemolink Clinical Trials Details .....	163
Table 41 Hemolink Clinical Trial: Tracking Information .....	164
Table 42 Hemolink Clinical Trial: Descriptive Information.....	164
Table 43 Hemolink Clinical Trial: Recruitment Information.....	165
Table 44 Hemolink Clinical Trial: Administrative Information .....	167
Table 45 HemAssist: Raw Material and Method Overview .....	168
Table 46 HemAssist: Product Characteristics .....	168

Table 47 HemAssist: Advantages and Disadvantages.....	170
Table 48 Hemopure: Raw Material and Method Overview.....	171
Table 49 Hemopure: Product Characteristics.....	172
Table 50 Hemopure: Advantages and Disadvantages.....	172
Table 51 Hemopure: List of Clinical Trials Registered.....	174
Table 52 Hemopure Clinical Trial: Patient Information.....	175
Table 53 Hemopure Clinical Trial: Details.....	176
Table 54 Summary of the Red-Blood-Cell-Controlled Phase 2 and Phase 3 Clinical Trial Performed by Biopure Corp.....	178
Table 55 Red-Blood-Cell-Controlled Clinical Trial Performed on Surgical Patients, by Dosage and Effects.....	179
Table 56 Hemopure Clinical Trial: Tracking Information.....	180
Table 57 Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia.....	181
Table 58 Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia.....	182
Table 59 Administrative Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia.....	184
Table 60 A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects.....	184
Table 61 Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects.....	186
Table 62 Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects.....	188
Table 63 Administrative Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects.....	189
Table 64 Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia.....	189
Table 65 Tracking Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia.....	190
Table 66 Descriptive Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia.....	190
Table 67 Recruitment Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia.....	192
Table 68 Administrative Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia.....	193
Table 69 Hemospan: Raw Material and Method Overview.....	194
Table 70 Hemospan: Product Characteristics.....	194
Table 71 Hemospan: Advantages and Disadvantages.....	195
Table 72 Clinical Studies with Hemospan: Completed and Ongoing.....	196
Table 73 Hemospan Clinical Trial: Details.....	196
Table 74 Hemospan Clinical Trial: Tracking Information.....	197
Table 75 Hemospan Clinical Trial: Descriptive Information.....	199
Table 76 Hemospan Clinical Trial: Recruitment Information.....	201
Table 77 Hemospan Clinical Trial: Administrative Information.....	202
Table 78 Hemotech: Raw Material and Method Overview.....	203
Table 79 HemoTech: Advantages and Disadvantages.....	203
Table 80 HemoTech Clinical Trials: Details.....	205
Table 81 HemoTech Clinical Trial: Tracking Information.....	205
Table 82 HemoTech Clinical Trial: Descriptive Information.....	206
Table 83 HemoTech Clinical Trial: Recruitment Information.....	209
Table 84 HemoTech Clinical Trial: Administrative Information.....	210
Table 85 DDFPe: Company Product Range and Description.....	211
Table 86 DDFPe: Raw Material and Method Overview.....	212
Table 87 DDFPe: Advantages and Disadvantages.....	212

Table 88 DDFPeClinical Trials: Details .....	213
Table 89 DDFPe Clinical Trial: Tracking Information.....	214
Table 90 DDFPe Clinical Trial: Descriptive Information .....	214
Table 91 DDFPe Clinical Trial: Recruitment Information .....	218
Table 92 DDFPe Clinical Trial: Administrative Information.....	219
Table 93 Oxycyte: Raw Material and Method Overview .....	220
Table 94 Oxycyte: Advantages and Disadvantages.....	221
Table 95 Oxycyte Clinical Trials: Details.....	222
Table 96 Oxycyte Clinical Trial: Tracking Information.....	222
Table 97 Descriptive Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI) .....	223
Table 98 Recruitment Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI) .....	226
Table 99 Administrative Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI) .....	228
Table 100 Details of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury .....	229
Table 101 Tracking Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury .....	229
Table 102 Descriptive Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury ..	230
Table 103 Recruitment Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury	231
Table 104 Administrative Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury .....	232
Table 105 Oxygent: Raw Material and Method Overview.....	233
Table 106 Oxygent: Advantages and Disadvantages .....	233
Table 107 Oxygent: Clinical Trials .....	234
Table 108 Vidaphor: Raw Material and Method Overview .....	237
Table 109 Vidaphor: Advantages and Disadvantages.....	238
Table 110 Vidaphor: Clinical Trial .....	239
Table 111 PHER-O2: Raw Material and Method Overview .....	240
Table 112 PHER-O2: Advantages and Disadvantages .....	240
Table 113 PHER-O2: Clinical Trials .....	242
Table 114 PolyHeme: Raw Material and Method Overview .....	243
Table 115 PolyHeme: Product Characteristics.....	244
Table 116 PolyHeme: Advantages and Disadvantages .....	244
Table 117 Polyheme Clinical Trials: Patient Information.....	246
Table 118 PolyHeme Clinical Trial: Details.....	246
Table 119 PolyHeme Clinical Trial: Tracking Information .....	247
Table 120 PolyHeme Clinical Trial: Descriptive Information.....	247
Table 121 PolyHeme Clinical Trial: Recruitment Information .....	248
Table 122 PolyHeme Clinical Trial: Administrative Information .....	249
Table 123 Sanguinate: Raw Material and Method Overview .....	250
Table 124 Sanguinate: Advantages and Disadvantages.....	250
Table 125 Sanguinate: Clinical Trials.....	251
Table 126 Sanguinate Clinical Trial: Details .....	253
Table 127 Sanguinate Clinical Trial: Tracking Information .....	253
Table 128 Sanguinate Clinical Trial: Descriptive Information .....	254
Table 129 Sanguinate Clinical Trial: Recruitment Information .....	255
Table 130 Sanguinate Clinical Trial: Administrative Information .....	257
Table 131 Alliance Pharmaceutical Corp: Company and Product Snapshot.....	259
Table 132 Baxter International Inc.: Company and Product Snapshot.....	261
Table 133 Biopure Corp: Company and Product Snapshot.....	263
Table 134 FluorO2 Therapeutics Inc.: Company and Product Snapshot .....	264



Table 135 HemoBioTech, Inc.: Company and Product Snapshot.....	266
Table 136 HemoBioTech, Inc.: Company and Product Snapshot.....	267
Table 137 Northfield Laboratories Inc.: Company and Product Snapshot .....	268
Table 138 Prolong Pharmaceuticals, LLC: Company and Product Snapshot .....	270
Table 139 Sangart, Inc: Company and Product Snapshot.....	272
Table 140 Sanguine Biosciences: Company and Product Snapshot.....	273
Table 141 Tenax Therapeutics, Inc.: Company and Product Snapshot.....	275
Table 142 Therapure Biopharma Inc.: Company and Product Snapshot.....	276
Table 143 Abbreviations Used in Artificial Blood Market.....	279

# List of Figures

Summary Figure Global Potential Artificial Blood Market, 2022–2027 (\$ Millions).....	10
Figure 1 Medical Applications of Human Red Blood Cells .....	13
Figure 2 Total Number of Surgeries and Death Cases in the World, 2017–2022 (Thousands) .....	26
Figure 3 Total Number of Blood Units Transfused in the World, 2017–2027 (Millions) .....	27
Figure 4 Global Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	30
Figure 5 Artificial Blood Manufactured from Different Sources.....	32
Figure 6 Historical Events of HBOCs Developed Using Recombinant Technology .....	35
Figure 7 Classification of Modified Hemoglobin Solution Based on Methods .....	36
Figure 8 Classification of Different Types of Oxygen Carriers.....	42
Figure 9 Generations of Perfluorocarbon Emulsions.....	46
Figure 10 Advantages and Disadvantages of PFC Emulsions .....	50
Figure 11 Development of HBOCs.....	52
Figure 12 Advantages and Disadvantages of HBOCs .....	56
Figure 13 Global Potential Artificial Blood Market, by Application, 2022–2027 (\$ Millions) .....	59
Figure 14 United States: Country Snapshot.....	63
Figure 15 Heart Disease Trend in the United States.....	64
Figure 16 Cancer Disease Trend in the United States.....	65
Figure 17 Transport Accident Trend in the United States .....	65
Figure 18 Blood Supply in the United States .....	66
Figure 19 Blood Demand in the United States.....	67
Figure 20 United States: Potential Artificial Blood Market, 2022–2027.....	67
(\$ Millions) .....	67
Figure 21 Canada: Country Snapshot.....	68
Figure 22 Heart Disease Trend in Canada .....	69
Figure 23 Cancer Disease Trend in Canada.....	70
Figure 24 Transport Accident Trend in Canada .....	71
Figure 25 Blood Supply in Canada.....	72
Figure 26 Blood Demand in Canada.....	72
Figure 27 Canada: Potential Artificial Blood Market, 2022–2027 .....	73
(\$ Millions) .....	73
Figure 28 Mexico: Country Snapshot.....	74
Figure 29 Heart Disease Trend in Mexico .....	75
Figure 30 Cancer Disease Trend in Mexico .....	76
Figure 31 Transport Accident Trend in Mexico.....	77
Figure 32 Blood Supply in Mexico.....	78
Figure 33 Blood Demand in Mexico .....	78
Figure 34 Mexico: Potential Artificial Blood Market, 2022–2027.....	79
(\$ Millions) .....	79
Figure 35 Germany: Country Snapshot.....	80
Figure 36 Heart Disease Trend in Germany .....	81
Figure 37 Cancer Disease Trend in Germany.....	82
Figure 38 Transport Accident Trend in Germany.....	83
Figure 39 Blood Supply in Germany.....	84
Figure 40 Blood Demand in Germany.....	84
Figure 41 Germany: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	85
Figure 42 France: Country Snapshot.....	86
Figure 43 Heart Disease Trend in France .....	87

Figure 44 Cancer Disease Trend in France .....	87
Figure 45 Transport Accident Trend in France.....	88
Figure 46 Blood Supply in France.....	89
Figure 47 Blood Demand (RBCs Transfused) in France.....	89
Figure 48 France: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	90
Figure 49 United Kingdom: Country Snapshot .....	91
Figure 50 Heart Disease Trend in the U.K. ....	92
Figure 51 Cancer Disease Trend in the U.K. ....	93
Figure 52 Transport Accident Trend in the U.K.....	94
Figure 53 Blood Supply in the U.K.....	95
Figure 54 Blood Demand in the U.K.....	95
Figure 55 U.K.: Potential Artificial Blood Market, 2022–2027 (\$ Millions).....	96
Figure 56 Italy: Country Snapshot.....	97
Figure 57 Heart Disease Trend in Italy .....	98
Figure 58 Cancer Disease Trend in Italy .....	99
Figure 59 Transport Accident Trend in Italy.....	100
Figure 60 Blood Supply in Italy.....	101
Figure 61 Blood Demand in Italy.....	101
Figure 62 Italy: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	102
Figure 63 Spain: Country Snapshot.....	103
Figure 64 Heart Disease Trend in Spain .....	104
Figure 65 Cancer Disease Trend in Spain .....	104
Figure 66 Transport Accident Trend in Spain.....	105
Figure 67 Blood Supply in Spain.....	106
Figure 68 Blood Demand in Spain.....	106
Figure 69 Spain: Potential Artificial Blood Market, 2022–2027 (\$ Millions).....	107
Figure 70 Russia: Country Snapshot .....	108
Figure 71 Heart Disease Trend in Russia.....	109
Figure 72 Cancer Disease Trend in Russia.....	110
Figure 73 Transport Accident Trend in Russia .....	111
Figure 74 Blood Supply in Russia .....	112
Figure 75 Blood Demand in Russia.....	112
Figure 76 Russia: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	113
Figure 77 China: Country Snapshot.....	114
Figure 78 Heart Disease Trend in China.....	115
Figure 79 Cancer Disease Trend in China.....	115
Figure 80 Transport Accident Trend in China .....	116
Figure 81 Blood Supply in China .....	117
Figure 82 Blood Demand in China.....	117
Figure 83 China: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	118
Figure 84 India: Country Snapshot.....	119
Figure 85 Heart Disease Trend in India .....	120
Figure 86 Cancer Disease Trend in India .....	121
Figure 87 Transport Accident Trend in India .....	122
Figure 88 Blood Supply in India.....	123
Figure 89 Blood Demand in India.....	124
Figure 90 India: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	125
Figure 91 Japan: Country Snapshot .....	126
Figure 92 Heart Disease Trend in Japan.....	127
Figure 93 Cancer Disease Trend in Japan.....	128

Figure 94 Transport Accident Trend in Japan .....	129
Figure 95 Blood Supply in Japan .....	130
Figure 96 Blood Demand in Japan .....	130
Figure 97 Japan: Potential Artificial Blood Market, 2022–2027 .....	131
(\$ Millions) .....	131
Figure 98 Australia: Country Snapshot .....	132
Figure 99 Heart Disease Trend in Australia.....	133
Figure 100 Cancer Disease Trend in Australia .....	134
Figure 101 Transport Accident Trend in Australia .....	135
Figure 102 Blood Supply in Australia .....	136
Figure 103 Blood Demand in Australia .....	136
Figure 104 Australia: Potential Artificial Blood Market, 2022–2027 .....	137
(\$ Millions) .....	137
Figure 105 Brazil: Country Snapshot.....	138
Figure 106 Heart Disease Trend in Brazil.....	139
Figure 107 Cancer Disease Trend in Brazil.....	140
Figure 108 Transport Accident Trend in Brazil.....	141
Figure 109 Blood Supply in Brazil.....	142
Figure 110 Blood Demand in Brazil.....	142
Figure 111 Brazil: Potential Artificial Blood Market, 2022–2027 (\$ Millions) .....	143
Figure 112 South Africa: Country Snapshot.....	144
Figure 113 Heart Disease Trend in South Africa .....	145
Figure 114 Cancer Disease Trend in South Africa .....	146
Figure 115 Transport Accident Trend in South Africa.....	147
Figure 116 Blood Supply in South Africa.....	148
Figure 117 Blood Demand in South Africa.....	148
Figure 118 South Africa: Potential Artificial Blood Market, 2022–2027 (\$ Millions).....	149
Figure 119 Current Competition in the Global Artificial Blood Market (I), 2020–2022.....	156
Figure 120 Current Competition in the Global Artificial Blood Market (II), 2022–2027.....	157
Figure 121 Artificial Blood: Parameters for Product Analysis.....	159
Figure 122 Hemolink: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications) .	162
Figure 123 HemAssist: Production Flow Chart .....	169
Figure 124 HemAssist: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)	170
Figure 125 Hemopure: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)	173
Figure 126 Hemospan: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)	195
Figure 127 HemoTech: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)	204
Figure 128 DDFPe: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications).....	213
Figure 129 Oxycyte: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications).....	221
Figure 130 Oxygent: Product Analysis (Based on Safety, Effectiveness, Cost, And Legal Implications)...	234
Figure 131 Vidaphor: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications) ..	238
Figure 132 PHER-O2: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications) ...	241
Figure 133 PolyHeme: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications) .	245
Figure 134 Sanguinate: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)	251



*About BCC Research*



## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Membership*

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781-205-2429.



## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-688-2  
April 2018